在STEMI患者的初级穿皮冠状动脉干预后,冠状动脉扩张前后冠状动脉血流的变化
1Department of Cardiology, People's Hospital of Yingshan County, Huanggang, Hubei Province, People's Republic of China.
Medicine
|November 19, 2024
概括
在ST段升高心肌梗塞的初级穿皮冠状动脉干预期间的扩张后,冠状动脉血流可能会恶化,并增加无反流/缓慢流事件. 然而,当心肌梗塞框架数在2325.25以下时,这种风险会降低,当支架后纠正的血栓溶解在心肌梗塞框架数下降时.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 血管生物学 血管生物学
背景情况:
- ST段升高心肌梗塞 (STEMI) 需要迅速恢复冠状动脉血流.
- 初级穿皮冠状动脉干预 (PPCI) 是STEMI的关键治疗方法.
- 讨论了PPCI后后扩张在优化结果中的作用,特别是关于其对微血管功能的影响.
研究的目的:
- 研究STEMI患者在PPCI后冠状动脉扩张后对冠状动脉血流和微血管并发症的影响.
- 评估心肌梗塞框架计数 (CTFC) 中纠正血栓溶解的变化以及无回流/缓慢流的发生率.
- 为了确定扩张后不良微血管事件的预测因子.
主要方法:
- 对419名接受PPCI的STEMI患者进行了回顾性队列研究.
- 在心肌梗塞框架计数 (CTFC) 中使用纠正的血栓溶解对冠状动脉血流的分析,在扩张前后进行.
- 评估最终的定量冠状动脉血管学和无回流/缓慢流的发生率.
- 经过扩张后患者与未经过扩张后患者之间的比较.
主要成果:
- 在259名患者中进行了扩张后的治疗,通常与化斑块,更长,更大或重叠的支架有关.
- 经过扩张后的患者显示CTFC值显著增加 (3.54 ± 10.54,P < .001).
- 没有回流/缓慢流的发生率在扩张后组增加了114% (P < .001) 与非扩张后组相比.
- 扩张后的策略与没有回流/缓慢流的可能性较低有关,如果后支架CTFC为<23.25 (AUC:0.817).
结论:
- 在接受PPCI的STEMI患者的扩张后可以加剧冠状动脉血流障碍并增加无反流/缓慢流的事件.
- 扩张后的有害影响在后支架CTFC低于23.25.25时就会减轻.
- 在决定在STEMI的PPCI期间进行后扩张时,仔细考虑CTFC指示的微血管状况至关重要.
更多相关视频
相关概念视频
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...